The University of Calgary’s Hotchkiss Brain Institute is poised to launch an innovative clinical trial investigating the use of psilocybin in treating...
Depression remains one of the most challenging mental health conditions, affecting millions worldwide with varying degrees of severity. Traditional treatments...
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed...
Tulum and Oaxaca couldn’t be more different in terms of their cultures surrounding psychedelic tourism. Here’s a glimpse at what to expect.
Missouri’s legislative body, the House of Representatives, has recently endorsed a budget legislation earmarking $10 million of the state’s opioid...
VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company...
TORONTO, April 05, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...